Searchable abstracts of presentations at key conferences in endocrinology

ea0077p197 | Metabolism, Obesity and Diabetes | SFEBES2021

Case report of a Patient With Maturity Onset Diabetes of the Young 6: a novel NEUROD1 mutation

Colosimo Santo , Baracco Bianca , Brodosi Lucia

Introduction: Maturity onset diabetes of the young (MODY) is a group of monogenic, autosomal, dominant diseases characterized by a single genetic mutation that results in beta-cells disfunction with consequent hyperglycemia. It Accounts for 1-5% of all cases of diabetes. At the moment, optimal treatment has not been established and it relies on the individual response. A mutation of NEUROD1 gene, a transcription factor expressed by pancreatic and nervous tissues, has been foun...

ea0086p212 | Metabolism, Obesity and Diabetes | SFEBES2022

Can improved glycaemic control improve NAFLD independent of weight loss in patients with type 2 diabetes?

Colosimo Santo , Tan Garry , Marchesini Giulio , Tomlinson Jeremy

Aim: The current focus for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) is lifestyle intervention with the aim of significant weight loss. NAFLD is tightly associated with type 2 diabetes (T2D) and obesity. In patients with T2D, glucose lowering agents that promote weight loss have shown a beneficial impact on NAFLD. However, it remains unclear as to whether glucose lowering can improve NALFD in patients with T2D, independent of weight loss.<p class="abstext"...

ea0077lb48 | Late Breaking | SFEBES2021

Post-HUS diabetes mellitus in 3 years old child: the challenging management of glucose control and the advantages of SAP therapy initiation

Grancini Valeria , Colosimo Santo , Gaglio Alessia , Resi Veronica , Giarratana Laura , Adinolfi Valerio , Orsi Emanuela

Introduction: Hemolytic-uremic syndrome (HUS) is a clinical condition characterized by nonimmune hemolytic anemia, thrombocytopenia and progressive kidney failure mediated by E.Coli Shiga-like toxin. In rare cases the inflammatory process may lead to beta-cell necrosis and, hence, overt diabetes mellitus. Post-HUS DM is characterized by severe insulin depletion and very high insulin sensitivity, making its therapeutic management particularly challenging....

ea0065p183 | Metabolism and Obesity | SFEBES2019

Hepatic effects of new anti-diabetic drugs: real world data from a retrospective study

Colosimo Santo , Brodosi Lucia , Marchignoli Francesca , Barbanti Francesca A , Marchesini Giulio , Petroni Maria Letizia

Background and aims: There is evidence that new anti-diabetic drugs may limit liver disease progression, reduce liver fat and normalize serum aminotranferase levels in patients with NAFLD. We compared the effectiveness of new drug classes on liver fat in T2DM patients by means of surrogate markers.Materials and methods: In an observational retrospective study we analysed the 12-month time-courses of clinical and anthropometric data of T2DM cases treated ...

ea0061cd1.1 | Case Discussions: complex clinical cases 1.0 | OU2019

Lifestyle intervention enhances weight loss and metabolic control in GLP-1RA-initiating subjects with T2DM

Colosimo Santo , Montesi Luca , Caletti Turchese , Marchesini Giulio , Petroni Maria Letizia

We retrospectively studied the effect on BMI and metabolic control (HbA1c within therapeutic targets) of structured lifestyle intervention associated with glucagon-like-1 receptor agonists (GLP-1RA) compared to GLP-1RA alone in patients with Type 2 diabetes (T2DM).Materials and method: The anthropometric and clinical data of 525 T2DM patients who started therapy with GLP-1RA were collected in a comprehensive database with follow-up of 24 months. Accordin...